Inspire Medical Systems (NYSE:INSP) Rating Reiterated by Mizuho

Inspire Medical Systems (NYSE:INSP)‘s stock had its “buy” rating reiterated by equities research analysts at Mizuho in a research report issued on Wednesday, Benzinga reports. They currently have a $250.00 target price on the stock. Mizuho’s price target indicates a potential upside of 16.27% from the stock’s current price.

A number of other analysts have also weighed in on INSP. Stifel Nicolaus reiterated a “hold” rating and set a $210.00 target price on shares of Inspire Medical Systems in a report on Tuesday, January 2nd. Truist Financial reissued a “buy” rating and set a $280.00 price objective on shares of Inspire Medical Systems in a research report on Wednesday, March 20th. KeyCorp assumed coverage on shares of Inspire Medical Systems in a research note on Tuesday, February 6th. They set an “overweight” rating and a $278.00 target price on the stock. Wells Fargo & Company cut shares of Inspire Medical Systems from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $245.00 to $187.00 in a research note on Wednesday, December 13th. Finally, Morgan Stanley started coverage on shares of Inspire Medical Systems in a report on Tuesday, March 19th. They issued an “overweight” rating and a $250.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $271.29.

Inspire Medical Systems Stock Up 0.7 %

Shares of INSP stock opened at $215.02 on Wednesday. The firm has a market capitalization of $6.52 billion, a P/E ratio of -290.57 and a beta of 1.35. Inspire Medical Systems has a twelve month low of $123.27 and a twelve month high of $330.00. The stock’s fifty day simple moving average is $198.23 and its 200 day simple moving average is $181.19.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Tuesday, February 6th. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.53. The business had revenue of $192.51 million during the quarter, compared to analyst estimates of $186.75 million. Inspire Medical Systems had a negative return on equity of 3.93% and a negative net margin of 3.39%. The firm’s revenue was up 39.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.10 EPS. As a group, equities research analysts expect that Inspire Medical Systems will post -0.35 EPS for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, Director Jerry C. Griffin sold 554 shares of the firm’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $197.81, for a total transaction of $109,586.74. Following the sale, the director now directly owns 10,636 shares of the company’s stock, valued at approximately $2,103,907.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Inspire Medical Systems news, Director Jerry C. Griffin sold 554 shares of Inspire Medical Systems stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $197.81, for a total transaction of $109,586.74. Following the transaction, the director now directly owns 10,636 shares of the company’s stock, valued at $2,103,907.16. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Randy Ban sold 3,060 shares of Inspire Medical Systems stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $182.01, for a total transaction of $556,950.60. Following the completion of the sale, the insider now owns 3,029 shares of the company’s stock, valued at approximately $551,308.29. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,339 shares of company stock worth $4,003,381. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Inspire Medical Systems

Several institutional investors have recently bought and sold shares of the stock. Resurgent Financial Advisors LLC bought a new stake in shares of Inspire Medical Systems in the 2nd quarter valued at approximately $25,000. Altshuler Shaham Ltd bought a new position in shares of Inspire Medical Systems in the fourth quarter valued at about $29,000. McGlone Suttner Wealth Management Inc. acquired a new position in shares of Inspire Medical Systems during the 4th quarter worth about $27,000. Parkside Financial Bank & Trust bought a new stake in Inspire Medical Systems in the 1st quarter valued at approximately $37,000. Finally, Meeder Asset Management Inc. raised its stake in shares of Inspire Medical Systems by 7,850.0% during the 4th quarter. Meeder Asset Management Inc. now owns 159 shares of the company’s stock worth $40,000 after purchasing an additional 157 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.